TELAPREVIR- BASED THERAPY IN G1 HCV-INFECTED PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN: REALIZE TRIAL FINAL RESULTS

被引：0
|
作者：
Foster, G. [1 ]
Zeuzem, S. [2 ]
Andreone, P. [3 ]
Pol, S. [4 ,5 ]
Lawitz, E. [6 ]
Diago, M. [7 ]
Roberts, S. [8 ]
Focaccia, R. [9 ]
Younossi, Z. [10 ]
H, A. [11 ]
Heeswijk, R. V. [12 ]
de Meyer, S. [12 ]
Luo, D. [13 ]
Picchio, G. [13 ]
Beumont, M. [12 ]
机构：
[1] Queen Mary Univ London, Inst Cell & Mol Sci, London, England
[2] Goethe Univ Frankfurt, Med Ctr, D-60054 Frankfurt, Germany
[3] Univ Bologna, Bologna, Italy
[4] Univ Paris 05, INSERM, U567, Paris, France
[5] Hop Cochin, AP HP, F-75674 Paris, France
[6] Alamo Med Res, San Antonio, TX USA
[7] Hosp Gen Valencia, Valencia, Spain
[8] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[9] Emilio Ribas Infect Dis Inst, Sao Paulo, Brazil
[10] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA USA
[11] Med Univ Warsaw, Warsaw, Poland
[12] Tibotec BVBA, Beerse, Belgium
[13] Tibotec Inc, Titusville, NJ USA
来源：
GUT | 2011年 / 60卷
关键词：
D O I：
10.1136/gutjnl-2011-300857b.3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP03
引用
收藏
页码：A50 / A51
页数：6
相关论文
共 50 条
  • [31] An Early Viral Response to Standard Interferon-Alpha Identifies Resistance to Combination Therapy With Peginterferon and Ribavirin in Patients Infected by HCV Genotype 1
    Toyoda, Hidenori
    Kumada, Takashi
    Kiriyama, Seiki
    Tanikawa, Makoto
    Hisanaga, Yasuhiro
    Kanamori, Akira
    Tada, Toshifumi
    Takagi, Makiko
    Hiramatsu, Takeshi
    Hosokawa, Takanori
    Arakawa, Takahiro
    Fujimori, Masashi
    JOURNAL OF MEDICAL VIROLOGY, 2010, 82 (09) : 1537 - 1544
  • [32] SVR Results of Prove3, a Phase 2B Clinical Trial Assessing Safety and Efficacy of Telaprevir in Hepatitis C Genotype-1-Infected Patients with Prior Non-Response, Viral Breakthrough or Relapse to Peginterferon-Alfa-2a/B and Ribavirin Therapy
    Di Bisceglie, Adrian M.
    Muir, Andrew M. J.
    Adda, Nathalie
    Jacobson, Ira M.
    Afdhal, Nezam H.
    Heathcote, E. Jenny
    Zeuzem, Stefan
    Reesink, Henk W.
    Terrault, Norah
    Bsharat, Mohammad
    George, Shelley
    Manns, Michael P.
    McHutchison, John
    GASTROENTEROLOGY, 2009, 136 (05) : A116 - A116
  • [33] Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4
    Domagalski, Krzysztof
    Pawlowska, Magorzata
    Tretyn, Andrzej
    Halota, Waldemar
    Tyczyno, Magorzata
    Kozielewicz, Dorota
    Dybowska, Dorota
    HEPATITIS MONTHLY, 2013, 13 (11)
  • [34] Response to peginterferon plus ribavirin and subsequent retreatment with telaprevir-based triple therapy in a patient with chronic lymphocytic leukaemia and chronic HCV genotype 1b infection
    Christensen, Stefan
    Gillessen, Anton
    INFECTIOUS AGENTS AND CANCER, 2014, 9
  • [35] Response to peginterferon plus ribavirin and subsequent retreatment with telaprevir-based triple therapy in a patient with chronic lymphocytic leukaemia and chronic HCV genotype 1b infection
    Stefan Christensen
    Anton Gillessen
    Infectious Agents and Cancer, 9
  • [36] A PHASE 2B STUDY OF TELAPREVIR WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN HEPATITIS C GENOTYPE 1 NULL AND PARTIAL RESPONDERS AND RELAPSERS FOLLOWING A PRIOR COURSE OF PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: PROVE3 INTERIM RESULTS
    McHutchison, John G.
    Shiffman, Mitchell L.
    Terrault, Norah
    Manns, Michael P.
    Di Bisceglie, Adrian M.
    Jacobson, Ira M.
    Afdhal, Nezom H.
    Heathcote, E. Jenny
    Zeuzem, Stefan
    Reesink, Hendrik W.
    George, Shelley
    Adda, Nathalie
    Muir, Andrew J.
    HEPATOLOGY, 2008, 48 (04) : 431A - 432A
  • [37] STANDARD VERSUS HIGH DOSE RIBAVIRIN IN COMBINATION WITH PEGINTERFERON ALFA-2A (40KD) IN GENOTYPE 1 (G1) HCV PATIENTS COINFECTED WITH HIV: FINAL RESULTS OF THE PARADIGM STUDY
    Rodriguez-Torres, Maribel
    Slim, Jihad
    Bhatti, Laveeza
    Sterling, Richard K.
    Sulkowski, Mark S.
    Hassanein, Tarek
    Serrao, Rosario
    Sola, Ricard
    Passe, Sharon
    Stancic, Saray
    HEPATOLOGY, 2009, 50 (04) : 1022A - 1023A
  • [38] Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response in Genotype 1 Chronic HCV and Allowed for Shorter Treatment Duration in Treatment-naive and Prior Relapser Patients
    Everson, Gregory
    Dusheiko, Geoffrey
    Pol, Stanislas
    Nelson, David
    Muir, Andrew
    Andreone, Pietro
    Kauffman, Robert
    Adda, Nathalie
    Wright, Christopher
    Bengtsson, Leif
    Martin, Marie
    Sankoh, Abdul
    George, Shelley
    Sherman, Kenneth
    Jacobson, Ira
    Zeuzem, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S113 - S114
  • [39] Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study
    Berg, Thomas
    Andreone, Pietro
    Pol, Stanislas
    Roberts, Stuart
    Younossi, Zobair
    Diago, Moises
    Lawitz, Eric J.
    Focaccia, Roberto
    Foster, Graham R.
    Horban, Andrzej
    Lonjon-Domanec, Isabelle
    DeMasi, Ralph
    Picchio, Gaston
    Luo, Donghan
    De Meyer, Sandra
    Zeuzem, Stefan
    LIVER INTERNATIONAL, 2015, 35 (02) : 448 - 454
  • [40] TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA2A AND RIBAVIRIN FOR 24 OR 48 WEEKS IN TREATMENT-NAiVE GENOTYPE 1 HCV PATIENTS WHO ACHIEVED AN EXTENDED RAPID VIRAL RESPONSE: FINAL RESULTS OF PHASE 3 ILLUMINATE STUDY
    Sherman, Kenneth E.
    Flamm, Steven L.
    Afdhal, Nezam H.
    Nelson, David R.
    Sulkowski, Mark S.
    Everson, Gregory T.
    Fried, Michael W.
    Kleber, Kristin
    Martins, Marie
    Sankoh, Abdul J.
    Kauffman, Robert S.
    George, Shelley
    Wright, Christopher I.
    Poordad, Fred
    HEPATOLOGY, 2010, 52 (04) : 401A - 402A
12345